Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Accumulated Expenses (2022 - 2025)

BioXcel Therapeutics (BTAI) has 4 years of Accumulated Expenses data on record, last reported at $35000.0 in Q3 2025.

  • For Q3 2025, Accumulated Expenses fell 98.73% year-over-year to $35000.0; the TTM value through Sep 2025 reached $35000.0, down 98.73%, while the annual FY2024 figure was $603000.0, 269.94% up from the prior year.
  • Accumulated Expenses reached $35000.0 in Q3 2025 per BTAI's latest filing, down from $41000.0 in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $13.7 million in Q1 2024 and bottomed at $21000.0 in Q1 2025.
  • Average Accumulated Expenses over 4 years is $3.9 million, with a median of $2.9 million recorded in 2022.
  • Peak YoY movement for Accumulated Expenses: skyrocketed 387.3% in 2024, then crashed 99.85% in 2025.
  • A 4-year view of Accumulated Expenses shows it stood at $3.2 million in 2022, then tumbled by 94.87% to $163000.0 in 2023, then soared by 269.94% to $603000.0 in 2024, then plummeted by 94.2% to $35000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Expenses were $35000.0 in Q3 2025, $41000.0 in Q2 2025, and $21000.0 in Q1 2025.